Drug-eluting stent study
This article was originally published in The Gray Sheet
Executive Summary
Guidant has received FDA permission to expand the SPIRIT III trial of its Xience V everolimus-eluting stent to the full cohort of 1,292 patients at up to 80 sites. The trial compares the Xience V, built on Guidant's cobalt-chromium Multi-Link Vision platform, with Boston Scientific's Taxus paclitaxel-eluting stent. The trial began in May (1"The Gray Sheet" May 9, 2005, p. 12)...